Royalty Pharma plc
NASDAQ:RPRX
27.99 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,354.554 | 2,237.215 | 2,289.463 | 2,122 | 1,814.254 | 1,794.894 | 1,597.93 | 1,877.41 | 1,652.42 |
| Cost of Revenue
| 560.656 | 5.67 | 22.996 | 88.111 | 1,019.321 | 135.96 | 33.267 | 0 | 0 |
| Gross Profit
| 1,793.898 | 2,231.545 | 2,266.467 | 2,033.889 | 794.933 | 1,658.934 | 1,564.663 | 1,877.41 | 1,652.42 |
| Gross Profit Ratio
| 0.762 | 0.997 | 0.99 | 0.958 | 0.438 | 0.924 | 0.979 | 1 | 1 |
| Reseach & Development Expenses
| 52 | 177.106 | 200.084 | 26 | 83.036 | 392.609 | 117.866 | 91.021 | 98.381 |
| General & Administrative Expenses
| 249.748 | 227.303 | 182.826 | 182 | 103.439 | 61.906 | 106.44 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 249.748 | 227.303 | 182.826 | 182 | 103.439 | 61.906 | 106.44 | 69.512 | 121.418 |
| Other Expenses
| -560.656 | 909.914 | 475.838 | 319 | -995.397 | -1.518 | -1.618 | -925.8 | -570.183 |
| Operating Expenses
| 862.404 | 1,314.323 | 858.748 | 527 | -808.922 | 430.448 | 658.238 | 1,086.333 | 789.982 |
| Operating Income
| 1,492.15 | 977.499 | 1,430.715 | 1,595 | 2,623.176 | 1,364.446 | 939.692 | 722.874 | 794.278 |
| Operating Income Ratio
| 0.634 | 0.437 | 0.625 | 0.752 | 1.446 | 0.76 | 0.588 | 0.385 | 0.481 |
| Total Other Income Expenses Net
| 207.938 | -747.435 | -189.514 | 107 | -161.757 | 408.924 | 644.065 | 39.021 | -35.57 |
| Income Before Tax
| 1,700.088 | 230.064 | 1,241.201 | 1,702 | 2,461.419 | 1,517.855 | 1,343.18 | 761.895 | 758.708 |
| Income Before Tax Ratio
| 0.722 | 0.103 | 0.542 | 0.802 | 1.357 | 0.846 | 0.841 | 0.406 | 0.459 |
| Income Tax Expense
| 565.254 | 187.232 | 762.447 | 1,147 | 349.333 | 433.365 | 542.655 | 195.988 | 177.282 |
| Net Income
| 1,134.834 | 42.832 | 478.754 | 495.198 | 2,348.535 | 1,377.729 | 1,210.025 | 565.907 | 581.426 |
| Net Income Ratio
| 0.482 | 0.019 | 0.209 | 0.233 | 1.294 | 0.768 | 0.757 | 0.301 | 0.352 |
| EPS
| 2.54 | 0.098 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EPS Diluted
| 1.88 | 0.098 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EBITDA
| 1,492.15 | 983.169 | 1,482.078 | 1,882 | 2,637.305 | 1,413.613 | 1,141.882 | 791.077 | 862.438 |
| EBITDA Ratio
| 0.634 | 0.439 | 0.647 | 0.887 | 1.454 | 0.788 | 0.715 | 0.421 | 0.522 |